Now in Its third year, the Neuropsychiatric Drug Development meeting is the definitive industry led meeting focused on unravelling the complexities of developing truly clinically transformative neuropsychiatric drugs.

Hear from new biotechs spearheading the innovation in the field and large pharma as we present the only opportunity for drug developers from across the landscape to share and gain translatable industry learning for neuropsychiatric disorders.


Top Three Reasons to Attend:

  • Gain an important market update on the progress of neuropsychiatric drug development through pioneering clinical case studies in schizophrenia, PTSD and addiction
  • Engage in critical discussions with industry experts and hear insights into tackling the fundamental and practical challenges hindering therapeutic success
  • Establish lasting connections with this dedicated community to accelerate your products to market and help patients in need

Here's Why our Expert Speakers are Excited to Attend:

" We are witnessing the beginnings of a renaissance in neuropsychiatric drug development that has the potential to completely change the way we treat commonand disabling disorders like schizophrenia and depression, the first new drugs for these serious brain disorders in many decades"

Steve Paul, Chairman of the Board, President & Chief Executive Officer, Karuna Therapeutics

"The NPD summit in 2020 is an exciting event that focuses on the current gaps and trends in Neuropsychiatric Drug Development "

Patricio O’Donnell, Executive Medical Director, Head of Neurocircuitry Modulation Biomarkers, Takeda